Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

KPV

Lys-Pro-Val, α-MSH (11-13)

Quick Stats
Studies 104
Trials 57
Score 2
2020 pubmed 24 citations

Subacute Neuropsychiatric Syndrome in Girls With <i>SHANK3</i> Mutations Responds to Immunomodulation.

Bey. Alexandra L AL; Gorman. Mark P MP; Gallentine. William W; Kohlenberg. Teresa M TM; Frankovich. Jennifer J; Jiang. Yong-Hui YH; Van Haren. Keith K

Key Findings

  • Peripubertal girls with SHANK3 mutations can develop a rapid, severe neuropsychiatric syndrome.
  • Standard antipsychotic drugs were largely ineffective for these symptoms.
  • Immunomodulatory therapy led to symptom improvement, with half of the patients fully recovering.

Practical Outcomes

  • For most biohackers this isn’t directly usable, but it hints that immune‑targeting approaches might help certain neuro‑psychiatric issues, especially when linked to genetic factors. Any such treatment should only be pursued under medical supervision and after thorough evaluation.

Summary

A small study looked at four teenage girls who have a rare genetic change (SHANK3 mutation) that caused a sudden drop in mental health, like mutism and hallucinations. Traditional meds didn’t help much, but treatments that calm the immune system seemed to improve their symptoms, and two girls got back to their normal level of function.

Abstract

Phenotypic and biological characterization of rare monogenic disorders represents 1 of the most important avenues toward understanding the mechanisms of human disease. Among patients with SH3 and multiple ankyrin repeat domains 3 (<i>SHANK3</i>) mutations, a subset will manifest neurologic regression, psychosis, and mood disorders. However, which patients will be affected, when, and why are important unresolved questions. Authors of recent studies suggest neuronal <i>SHANK3</i> expression is modulated by both inflammatory and hormonal stimuli. In this case series, we describe 4 independent clinical observations of an immunotherapy responsive phenotype of peripubertal-onset neuropsychiatric regression in 4 girls with pathogenic <i>SHANK3</i> mutations. Each child exhibited a history of stable, mild-to-moderate lifelong developmental disability until 12 to 14 years of age, at which time each manifested a similar, subacute-onset neurobehavioral syndrome. Symptoms included mutism, hallucinations, insomnia, inconsolable crying, obsessive-compulsive behaviors, loss of self-care, and urinary retention and/or incontinence. Symptoms were relatively refractory to antipsychotic medication but improved after immunomodulatory treatment. All 4 patients exhibited chronic relapsing courses during a period of treatment and follow-up ranging from 3 to 6 years. Two of the 4 girls recovered their premorbid level of functioning. We briefly review the scientific literature to offer a conceptual and molecular framework for understanding these clinical observations. Future clinical and translational investigations in this realm may offer insights into mechanisms and therapies bridging immune function and human behavior.

Study Information

Provider

pubmed

Year

2020

Date

2020-02-01T00:00:00.000Z

DOI

10.1542/peds.2019-1490

Citations

24

References

27